Literature DB >> 12118186

Biochemical characterization of the arginine degrading enzymes arginase and arginine deiminase and their effect on nitric oxide production.

Brian J Dillon1, Frederick W Holtsberg, C Mark Ensor, John S Bomalaski, Mike A Clark.   

Abstract

BACKGROUND: Nitric oxide (NO) is a biomediator believed to be synthesized primarily from extracellular arginine. Various methodologies have been used to inhibit NO synthesis so as to elucidate its physiological and pathophysiological functions. Several investigators have utilized various argin ine degrading enzymes as a means of lowering extracellular arginine. Arginase, most commonly derived from mammalian sources, has been most often used. However, arginase has failed to inhibit NO synthesis. Therefore, a systematic biochemical characterization of arginase and arginine deiminase (ADI) derived from M. Hominus was undertaken. MATERIAL/
METHODS: The murine macrophage cell line N-9 was treated with either arginase or arginine deiminase to determine the effect on intracellular and extracellular arginine and nitric oxide production.
RESULTS: Arginase was found to have an alkaline pH optima(approximately 9.5) with little enzyme activity at physiological pH. In contrast, the pH optima of ADI was approximately 6.5, retaining >70% of its activity at physiological pH. ADI had more than 1000 fold higher affinity for arginine (Km approximately 30 KM for ADI vs approximately 45 mM for arginase), and was able to lower arginine levels to a much greater extent than arginase. ADI, unlike arginase, was effective in lowering extracellular arginine in tissue culture media and inhibit NO production by the murine macrophage cell line N-9 in response to gamma interferon and LPS stimulation.
CONCLUSIONS: These data suggest that ADI may be useful for delineating the role of NO in a variety of biological systems as well as determining the role of extracellular arginine in its synthesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12118186

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  19 in total

Review 1.  Arginine deprivation, autophagy, apoptosis (AAA) for the treatment of melanoma.

Authors:  N Savaraj; M You; C Wu; M Wangpaichitr; M T Kuo; L G Feun
Journal:  Curr Mol Med       Date:  2010-06       Impact factor: 2.222

2.  Strategies for optimizing the serum persistence of engineered human arginase I for cancer therapy.

Authors:  Everett Stone; Lynne Chantranupong; Candice Gonzalez; Jamye O'Neal; Mridula Rani; Carla VanDenBerg; George Georgiou
Journal:  J Control Release       Date:  2011-10-06       Impact factor: 9.776

Review 3.  Arginine dependence of tumor cells: targeting a chink in cancer's armor.

Authors:  M D Patil; J Bhaumik; S Babykutty; U C Banerjee; D Fukumura
Journal:  Oncogene       Date:  2016-04-25       Impact factor: 9.867

Review 4.  Pegylated arginine deiminase: a novel anticancer enzyme agent.

Authors:  Lynn Feun; Niramol Savaraj
Journal:  Expert Opin Investig Drugs       Date:  2006-07       Impact factor: 6.206

5.  Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis.

Authors:  Randie H Kim; Jodi M Coates; Tawnya L Bowles; Gregory P McNerney; Julie Sutcliffe; Jae U Jung; Regina Gandour-Edwards; Frank Y S Chuang; Richard J Bold; Hsing-Jien Kung
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

6.  Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase.

Authors:  Tawnya L Bowles; Randie Kim; Joseph Galante; Colin M Parsons; Subbulakshmi Virudachalam; Hsing-Jien Kung; Richard J Bold
Journal:  Int J Cancer       Date:  2008-10-15       Impact factor: 7.396

Review 7.  Arginine depriving enzymes: applications as emerging therapeutics in cancer treatment.

Authors:  Neha Kumari; Saurabh Bansal
Journal:  Cancer Chemother Pharmacol       Date:  2021-07-26       Impact factor: 3.333

8.  Release of metabolic enzymes by Giardia in response to interaction with intestinal epithelial cells.

Authors:  Emma Ringqvist; J E Daniel Palm; Hanna Skarin; Adrian B Hehl; Malin Weiland; Barbara J Davids; David S Reiner; William J Griffiths; Lars Eckmann; Frances D Gillin; Staffan G Svärd
Journal:  Mol Biochem Parasitol       Date:  2008-02-15       Impact factor: 1.759

Review 9.  Arginine deprivation as a targeted therapy for cancer.

Authors:  L Feun; M You; C J Wu; M T Kuo; M Wangpaichitr; S Spector; N Savaraj
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

10.  Structural characterization of the enzymes composing the arginine deiminase pathway in Mycoplasma penetrans.

Authors:  Pablo Gallego; Raquel Planell; Jordi Benach; Enrique Querol; Josep A Perez-Pons; David Reverter
Journal:  PLoS One       Date:  2012-10-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.